BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 30-Jan-2019

(Q2 Un-audited): Consolidated EPS was Tk. 3.96 for October-December, 2018 as against Tk. 3.62 for October-December, 2017; Consolidated EPS was Tk. 7.98 for July-December, 2018 as against Tk. 7.43 for July-December, 2017. Consolidated NOCFPS was Tk. 7.32 for July-December, 2018 as against Tk. 8.09 for July-December, 2017. Consolidated NAV per share was Tk. 77.90 as on December 31, 2018 and Tk. 73.28 as on June 30, 2018.

SQURPHARMA 28-Jan-2019

The Company has informed that the Cash Dividend for the year ended on June 30, 2018 has been disbursed.

SQURPHARMA 24-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

SQURPHARMA 03-Jan-2019

The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2018 to the respective shareholders' BO Accounts on January 02, 2019.

SQURPHARMA 27-Dec-2018

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2018; unaudited financials up to September 30, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

SQURPHARMA 27-Nov-2018

Trading of the shares of the Company will resume on 28.11.2018 after record date.

SQURPHARMA 26-Nov-2018

Trading of the shares of the Company will remain suspended on record date i.e., 27.11.2018.

SQURPHARMA 22-Nov-2018

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 25.11.2018 to 26.11.2018. Trading of the shares of the Company will remain suspended on record date i.e., 27.11.2018.

SQURPHARMA 14-Nov-2018

(Q1 Un-audited): Consolidated EPS was Tk. 4.30 for July-September, 2018 as against Tk. 4.08 for July-September, 2017; Consolidated NOCFPS was Tk. 4.34 for July-September, 2018 as against Tk. 5.04 for July-September, 2017. Consolidated NAV per share was Tk. 82.82 as on September 30, 2018 and Tk. 78.41 as on June 30, 2018.

SQURPHARMA 07-Nov-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.

Previous Next page